[go: up one dir, main page]

MX2022006655A - Uso de nucleosomas libres de celulas como biomarcadores. - Google Patents

Uso de nucleosomas libres de celulas como biomarcadores.

Info

Publication number
MX2022006655A
MX2022006655A MX2022006655A MX2022006655A MX2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A
Authority
MX
Mexico
Prior art keywords
biomarkers
cell free
free nucleosomes
nucleosomes
vascular
Prior art date
Application number
MX2022006655A
Other languages
English (en)
Inventor
Mark Edward Eccleston
Jacob Vincent Micallef
Heather Wilson-Robles
Marielle Chantal Andree Herzog
Jason Bradley Terrell
Original Assignee
Belgian Volition Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belgian Volition Srl filed Critical Belgian Volition Srl
Publication of MX2022006655A publication Critical patent/MX2022006655A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a nucleosomas libres de células como biomarcadores en muestras de plasma para detectar cánceres vasculares o hematológicos.
MX2022006655A 2019-12-02 2020-12-02 Uso de nucleosomas libres de celulas como biomarcadores. MX2022006655A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962942596P 2019-12-02 2019-12-02
US202063088408P 2020-10-06 2020-10-06
PCT/EP2020/084328 WO2021110776A1 (en) 2019-12-02 2020-12-02 Use of cell free nucleosomes as biomarkers

Publications (1)

Publication Number Publication Date
MX2022006655A true MX2022006655A (es) 2022-09-07

Family

ID=73698838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006655A MX2022006655A (es) 2019-12-02 2020-12-02 Uso de nucleosomas libres de celulas como biomarcadores.

Country Status (15)

Country Link
US (1) US20230003735A1 (es)
EP (2) EP4070111B1 (es)
JP (2) JP7693670B2 (es)
KR (1) KR20220110794A (es)
CN (1) CN114829939A (es)
AU (1) AU2020395504A1 (es)
BR (1) BR112022010774A2 (es)
CA (1) CA3163181A1 (es)
ES (1) ES2988371T3 (es)
IL (1) IL293342A (es)
MX (1) MX2022006655A (es)
PL (1) PL4070111T3 (es)
TW (1) TW202134654A (es)
WO (1) WO2021110776A1 (es)
ZA (1) ZA202205916B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4155401A1 (en) * 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP4423501A1 (en) 2021-10-29 2024-09-04 Belgian Volition SRL Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
WO2023170298A1 (en) 2022-03-11 2023-09-14 Belgian Volition Srl Differential diagnosis method
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin
WO2024133225A1 (en) * 2022-12-19 2024-06-27 Belgian Volition Srl Calibration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
GB0413732D0 (en) * 2004-06-13 2004-07-21 Chroma Therapeutics Ltd Histone modification
EP2282208B1 (en) * 2009-08-03 2011-11-23 Universitätsklinikum Freiburg Methods and compounds for the diagnosis and treatment of cancer
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115099D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
WO2013084002A2 (en) 2011-12-07 2013-06-13 Singapore Volition Pte Limited Method for detecting nucleosome adducts
EP4155401A1 (en) * 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9388213B2 (en) * 2012-09-10 2016-07-12 The Rockefeller University Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof
CN111505305B (zh) 2014-10-29 2023-10-17 比利时意志有限责任公司 用于富集循环肿瘤dna的方法
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201518674D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
DK3759249T3 (da) * 2018-03-01 2023-10-30 Epicypher Inc Kvantificering af nukleosommodifikationer ved anvendelse af kemisk definerede rekombinante nukleosomer

Also Published As

Publication number Publication date
KR20220110794A (ko) 2022-08-09
WO2021110776A1 (en) 2021-06-10
PL4070111T3 (pl) 2025-02-03
JP2025124845A (ja) 2025-08-26
IL293342A (en) 2022-07-01
ZA202205916B (en) 2024-09-25
EP4070111B1 (en) 2024-08-21
BR112022010774A2 (pt) 2022-08-23
EP4435431A3 (en) 2024-10-16
EP4070111A1 (en) 2022-10-12
ES2988371T3 (es) 2024-11-20
AU2020395504A1 (en) 2022-06-23
CN114829939A (zh) 2022-07-29
JP2023503379A (ja) 2023-01-27
US20230003735A1 (en) 2023-01-05
JP7693670B2 (ja) 2025-06-17
EP4435431A2 (en) 2024-09-25
TW202134654A (zh) 2021-09-16
EP4070111C0 (en) 2024-08-21
CA3163181A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
ZA202205916B (en) Use of cell free nucleosomes as biomarkers
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
EP3816303A3 (en) Breast cancer detection kit or device, and method for detecting breast cancer
GB2511221A (en) Methods and compositions for classification of samples
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
EP3757225A3 (en) Pancreatic cancer detection kit or device, and detection method
MY186712A (en) Methods and compositions for inhibiting the interaction of menin with mll proteinss
EP4458849A3 (en) Biomarkers for pancreatic cancer
WO2018187496A8 (en) PLASMA PROTEIN PROFILING FOR THE EARLY PROGNOSIS OF LUNG CANCER
MX2017009768A (es) Ligadores lábiles para detección de biomarcadores.
EP3800253A3 (en) Prostate cancer detection kit or device, and detection method
HK1246828A1 (zh) 用於检测癌症的生物标志物组
EP4461824A3 (en) Detection kit or device and detection method for biliary tract cancer
MX2017014735A (es) Metilacion de promotor pd-l1 en cancer.
EP4365602A3 (en) Stomach cancer biomarker and detection method
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
EP3201812A4 (en) Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample
MX357429B (es) Predictores para el tratamiento del cáncer.
MX2019006005A (es) Metodos para la deteccion de cancer.
AU2018262331A1 (en) Methods for trapping and barcoding discrete biological units in hydrogel
MX2016016507A (es) Composiciones y metodos para tratar canceres.
WO2012167163A3 (en) Methods and compositions for detecting endometrial or ovarian cancer
WO2018187385A8 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING PANCREATIC CANCER
WO2014184684A3 (en) Methods and biomarkers for detection of hematological cancers
WO2015013455A3 (en) Methods and compositions for the treatment and diagnosis of cancer